Google Übersetzer
Immatics N.v.
About
11.62USD+0.56 +5.06%
Closed • Updated at 12:52 GMT+00:00Market Cap$1.56B
Volume461.7K
Beta0.54
RSI58.24
Immatics N.v. — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 21 2026
Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting
Apr 17 2026
PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma
Mar 5 2026
Immatics Announces Full Year 2025 Financial Results and Business Update
Dec 11 2025
Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress
Dec 5 2025
Immatics Announces $125 Million Underwritten Offering
Recent Videos
Immatics was founded in Tubingen and is based on foundational science around the PRAME antigen.
Apr 27, 2026
Decoding Risk: Introducing Immatics N.V.'s Sortino Ratio
Jan 19, 2026
Immatics N.V. Stock Price 5 Years Timelaps 📈 #stocks
Dec 22, 2025
Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline
Nov 12, 2025
Community Chat
Ask AI
Try asking